Northway Biotech has launched its Gene Therapy Center in Vilnius Lithuania, the first in the Baltic States. This state-of-the-art facility is the first building of the BIO CITY project, where the goal is to build Europe’s largest biotechnology hub and support innovative companies.
 
The 8,000 square meter facility is equipped with the latest technology to offer viral vector and plasmid cGMP manufacturing, cell banking and full characterization, and analytical and quality testing, including viral clearance studies.
 
The BIO CITY project, led by Northway Biotech, is rapidly expanding and will include additional facilities by 2030, enhancing capacity to help clients bring therapies to market.
 
Northway group is one of the Lithuanian biotechnology market leaders. The group’s biotechnology cluster comprises seven companies: five in Lithuania, one in the UK and one in the U.S. In the latter market, Northway is the largest biotechnology investor in the Baltic region. Together, these companies employ more than 200 professionals.